RecruitingPhase 1NCT04540107

Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

Metabolic Imaging of Patients With Lower Grade Glioma Using Hyperpolarized 13C Pyruvate

Sponsor

Susan Chang

Enrollment

300 participants

Start Date

Jan 11, 2017

Study Type

INTERVENTIONAL

Conditions

WHO Grade III Glioma WHO Grade II Glioma Recurrent WHO Grade III Glioma Recurrent World Health Organization (WHO) Grade II Glioma

Summary

This trial studies how well serial magnetic resonance (MR) imaging and MR spectroscopic imaging work in characterizing lower grade glioma. Diagnostic procedures, such as MR imaging and MR spectroscopic imaging, may detect serial changes in lower grade glioma. This study may help researchers learn more about practical ways of evaluating and standardizing treatment in patients with brain tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Hyperpolarized Carbon C 13 Pyruvate, a procedure called Magnetic Resonance Imaging, and others for people with recurrent who grade iii glioma, recurrent world health organization (who) grade ii glioma, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.